Search

Your search keyword '"Leslie Z. Benet"' showing total 546 results

Search Constraints

Start Over You searched for: Author "Leslie Z. Benet" Remove constraint Author: "Leslie Z. Benet"
546 results on '"Leslie Z. Benet"'

Search Results

1. Evaluating in vivo data for drug metabolism and transport: lessons from Kirchhoff’s Laws

2. Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?

3. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs

4. Ascorbic acid metabolites are involved in intraocular pressure control in the general population

5. TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling

6. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence

7. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs

8. The Uses and Advantages of Kirchhoff’s Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry

9. Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans

10. Calculating Pharmacokinetic Areas

11. Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance

12. Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption

14. The Critical Role of Passive Permeability in Designing Successful Drugs

15. Volume of Distribution is Unaffected by Metabolic Drug–Drug Interactions

16. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References

18. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing

19. Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies

20. Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions

21. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction

22. Evaluating Within‐Subject Variability for Narrow Therapeutic Index Drugs

23. Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization

24. Using Individualized Patient Data for Prediction of Population Dosing Recommendations Versus Predictions of Individualized Patient Dosing

25. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

26. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition

27. Investigating the Theoretical Basis for In Vitro–In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways

28. The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions

29. Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?

30. Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions

31. TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling

32. Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of in vitro methodologies vs. BDDCS classification

33. Batch‐to‐Batch and Within‐Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?

34. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI

36. Protein Binding and Hepatic Clearance: Re-Examining the Discrimination between Models of Hepatic Clearance with Diazepam in the Isolated Perfused Rat Liver Preparation

37. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis

38. A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs

39. How Transporters Have Changed Basic Pharmacokinetic Understanding

40. Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial

41. In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly

42. Can BDDCS illuminate targets in drug design?

43. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs

44. Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties

45. Ascorbic acid metabolites are involved in intraocular pressure control in the general population

46. BDDCS, the Rule of 5 and drugability

47. Batch‐to‐batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

48. Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics

49. The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation

50. Characterization of Fasiglifam-Related Liver Toxicity in Dogs

Catalog

Books, media, physical & digital resources